Gentian Diagnostics AS (GENT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gentian Diagnostics AS (GENT) has a cash flow conversion efficiency ratio of 0.208x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr42.59 Million ≈ $4.48 Million USD) by net assets (Nkr204.96 Million ≈ $21.57 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Gentian Diagnostics AS (GENT) defensive interval to measure how many days the company can operate on defensive assets alone.
Gentian Diagnostics AS - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Gentian Diagnostics AS's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Gentian Diagnostics AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gentian Diagnostics AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SERESCO (ACC.P.DESD.)-16
F:XV7
|
N/A |
|
JLS Co.Ltd
KQ:040420
|
0.043x |
|
PP Properti Tbk PT
JK:PPRO
|
0.001x |
|
Cantargia AB
ST:CANTA
|
0.943x |
|
Samwon Steel
KO:023000
|
0.020x |
|
Usak Seramik Sanayi AS
IS:USAK
|
-0.004x |
|
Crown Confec
KO:005740
|
0.020x |
|
Fiducial Office Solutions
PA:SACI
|
-0.086x |
Annual Cash Flow Conversion Efficiency for Gentian Diagnostics AS (2013–2025)
The table below shows the annual cash flow conversion efficiency of Gentian Diagnostics AS from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Gentian Diagnostics AS market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr204.96 Million ≈ $21.57 Million |
Nkr42.59 Million ≈ $4.48 Million |
0.208x | +199.65% |
| 2024-12-31 | Nkr194.05 Million ≈ $20.42 Million |
Nkr13.46 Million ≈ $1.42 Million |
0.069x | -34.22% |
| 2023-12-31 | Nkr146.64 Million ≈ $15.43 Million |
Nkr15.46 Million ≈ $1.63 Million |
0.105x | +216.49% |
| 2022-12-31 | Nkr154.17 Million ≈ $16.22 Million |
Nkr-13.95 Million ≈ $-1.47 Million |
-0.090x | +41.54% |
| 2021-12-31 | Nkr174.77 Million ≈ $18.39 Million |
Nkr-27.05 Million ≈ $-2.85 Million |
-0.155x | -293.16% |
| 2020-12-31 | Nkr194.58 Million ≈ $20.48 Million |
Nkr-7.66 Million ≈ $-806.16K |
-0.039x | +61.84% |
| 2019-12-31 | Nkr208.24 Million ≈ $21.91 Million |
Nkr-21.48 Million ≈ $-2.26 Million |
-0.103x | -132.78% |
| 2018-12-31 | Nkr245.87 Million ≈ $25.87 Million |
Nkr-10.90 Million ≈ $-1.15 Million |
-0.044x | +53.27% |
| 2017-12-31 | Nkr196.48 Million ≈ $20.67 Million |
Nkr-18.63 Million ≈ $-1.96 Million |
-0.095x | -38.67% |
| 2016-12-31 | Nkr115.54 Million ≈ $12.16 Million |
Nkr-7.90 Million ≈ $-831.48K |
-0.068x | -40.53% |
| 2015-12-31 | Nkr95.06 Million ≈ $10.00 Million |
Nkr-4.63 Million ≈ $-486.79K |
-0.049x | +81.55% |
| 2014-12-31 | Nkr7.39 Million ≈ $778.15K |
Nkr-1.95 Million ≈ $-205.27K |
-0.264x | -117.56% |
| 2013-12-31 | Nkr1.62 Million ≈ $170.46K |
Nkr2.43 Million ≈ $256.10K |
1.502x | -- |
About Gentian Diagnostics AS
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and… Read more